Clostridium Difficile Infection Recurrence
14
3
3
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
21.4%
3 terminated out of 14 trials
66.7%
-19.8% vs benchmark
36%
5 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients
Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
Bezlotoxumab Efficacy and Tolerability in Cancer Patient
Treatment for Clostridium-difficile Infection With IMM529